Previous 10 | Next 10 |
home / stock / brrgf / brrgf news
BERGEN, Norway , May 13, 2020 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), will announce its results for the first quarter 2020 on Tuesday 19 May 2020 . A webcast presentation by BerGenBio's senior management team will take place at 10 am CET . The presentation will webcast live a...
BERGEN, Norway , May 5, 2020 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need, is pleased to announce that it has raised NOK500m (gross) (€45.4 million) via an over...
BERGEN, Norway , April 28, 2020 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need, announces that bemcentinib has been selected as the first potential treatment to be fast-tr...
BERGEN, Norway , Jan. 29, 2020 /PRNewswire/ -- NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES, OR IN OR INTO THE UNITED STATES , CANADA , AUSTRALIA , THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, SOUTH AFRICA OR ...
Bergen, Norway-based BerGenBio ( OTCPK:BRRGF ) announces positive results from the first stage of its two-stage Phase 2 clinical trial evaluating lead candidate bemcentinib , combined with Merck's Keytruda (pembrolizumab), in patients with advanced non-small cell lung cancer (NSCLC) who...
- Phase II trial evaluating bemcentinib in combination with low-dose cytarabine (LDAC) in elderly AML patients unfit for intensive therapy is well tolerated and shows promising efficacy - Long duration of response (>9.9 mo, still maturing) with 50% CR/CRi in 6 evaluable newly diag...
BERGEN, Norway , Nov. 8, 2019 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, today presents comprehensive clinical and translational data from Cohort A of its Pha...
BERGEN, Norway , Sept. 27, 2019 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, is to provide study updates in two poster presentations from its Phase II clinical ...
BERGEN, Norway , Sept. 9, 2019 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, will present study updates from its Phase II clinical development programme with bemcent...
- Acute Myeloid Leukaemia (AML): Preliminary Phase II clinical shows promising efficacy for bemcentinib in combo with low-intensity chemo in elderly AML patients unfit for intensive therapy - Non small cell lung cancer (NSCLC): Phase II clinical data continues to show promising clinical ac...
News, Short Squeeze, Breakout and More Instantly...
Brent Resources Group Ltd Company Name:
BRRGF Stock Symbol:
OTCMKTS Market:
Brent Resources Group Ltd Website:
Bergenbio Presents Encouraging Updated Preliminary Data From Phase Ii Study In Relapsed Aml Patients At Eha Virtual Meeting Encouraging updated preliminary survival data more than double standard of care reported in relapsed AML patients PR Newswire BERGEN, Norway ...
BerGenBio Presents Updated Clinical Data From Two Phase II Studies Of Bemcentinib in AML and MDS Patients At Ash 2020 BERGEN, Norway , Dec. 6, 2020 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL...
BerGenBio Presents Phase II Bemcentinib Combination Study in NSCLC at Annual SITC Meeting PR Newswire BERGEN, Norway, Nov. 11, 2020 BERGEN, Norway , Nov. 11, 2020 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing...